https://autifony.com/wp-content/uploads/2022/05/autifony_therapeutics-Logo_RGB.svg00Wendy Kennedyhttps://autifony.com/wp-content/uploads/2022/05/autifony_therapeutics-Logo_RGB.svgWendy Kennedy2025-03-28 14:20:322025-03-28 14:33:41Kv3 Modulator AUT00201 can promote recovery post CNS trauma such as stroke via enhanced activity of parvalbumin interneurones
https://autifony.com/wp-content/uploads/2022/05/autifony_therapeutics-Logo_RGB.svg00Wendy Kennedyhttps://autifony.com/wp-content/uploads/2022/05/autifony_therapeutics-Logo_RGB.svgWendy Kennedy2025-03-28 14:17:152025-03-28 14:28:50Causal mutations in the genes encoding Kv3.1 and Kv3.2 have been increasingly linked to debilitating CNS diseases such as epilepsy, developmental encephalopathies, intellectual disability and autism
https://autifony.com/wp-content/uploads/2022/05/autifony_therapeutics-Logo_RGB.svg00Wendy Kennedyhttps://autifony.com/wp-content/uploads/2022/05/autifony_therapeutics-Logo_RGB.svgWendy Kennedy2025-03-28 14:07:222025-03-28 14:29:48Kv3 Modulator AUT00206 offers potential as a precision medicine approach for the treatment of progressive myoclonic epilepsy (EPM7)
https://autifony.com/wp-content/uploads/2022/05/autifony_therapeutics-Logo_RGB.svg00Wendy Kennedyhttps://autifony.com/wp-content/uploads/2022/05/autifony_therapeutics-Logo_RGB.svgWendy Kennedy2022-10-03 13:31:112022-10-04 11:08:41Autifony and collaborators publish the results from a clinical trial of AUT00206 in patients with schizophrenia
https://autifony.com/wp-content/uploads/2022/05/autifony_therapeutics-Logo_RGB.svg00Wendy Kennedyhttps://autifony.com/wp-content/uploads/2022/05/autifony_therapeutics-Logo_RGB.svgWendy Kennedy2022-10-03 13:29:102022-10-03 13:29:10Autifony and collaborators publish the results from a clinical trial of AUT00206 in patients with schizophrenia